The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast…

By R. Finn, J. Crown, I. Láng, K. Boér, I. Bondarenko, Sergey O. Kulyk, J. Ettl, Ravi B. Patel, T. Pintér, Marcus Schmidt and 8 more. The Lancet Oncology, 2015

1,577 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/8c15d90e1b2e3d3784527618ecfce33bc43a1d6c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Olivier Elemento
2. Arul M. Chinnaiyan
3. C. Sawyers

In Oncology

1. Nikolaus Schultz
2. Olivier Elemento
3. C. Sawyers
4. E. Scholar
5. A. Arora

In Pulmonary and Respiratory Medicine

1. Arul M. Chinnaiyan
2. C. Sawyers
3. Mark A. Rubin
4. M. Hallek

Citations in the corpus

• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018, neutral): “Any 6 (2) 2 (1) 6 (5) 9 (6) 6 (5) 15 (18)”
• Integrative clinical genomics of advanced prostate cancer (2015, positive): “Cell-cycle derangement, such as through CCND1 amplification or CDKN2A/B loss, may result in enhanced response to CDK4 inhibitors in other tumor types (Finn et al., 2015), and preclinical mCRPC models predict similar activity in prostate cancer (Comstock et al.”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, neutral): “metastatic breast cancer [60].”